| Summary of Net Revenue, Cost of Sales, Depreciation and Amortization, Operating Profit, Interest Expense, Income Tax (Expense) Benefit and Assets by Segment |
The following table shows, by segment: net revenue, cost of sales,
depreciation and amortization, operating profit, interest expense,
and income tax (expense) benefit for the three months and nine
months ended August 31, 2018:
|
|
|
|
|
|
|
|
|
| |
|
For the three months
ended August 31, 2018 |
|
|
For the nine months
ended August 31, 2018 |
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
7,776,339 |
|
|
$ |
20,475,020 |
|
|
Prepacyte®-CB
|
|
|
29,308 |
|
|
|
84,208 |
|
|
Public cord blood banking
|
|
|
65,575 |
|
|
|
65,575 |
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$ |
7,871,222 |
|
|
$ |
20,624,803 |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
2,149,778 |
|
|
$ |
5,431,359 |
|
|
Prepacyte®-CB
|
|
|
27,740 |
|
|
|
124,805 |
|
|
Public cord blood banking
|
|
|
308,662 |
|
|
|
308,662 |
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$ |
2,486,180 |
|
|
$ |
5,864,826 |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
43,008 |
|
|
$ |
97,674 |
|
|
Prepacyte®-CB
|
|
|
9,064 |
|
|
|
27,191 |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$ |
52,072 |
|
|
$ |
124,865 |
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,170,704 |
|
|
$ |
3,521,625 |
|
|
Prepacyte®-CB
|
|
|
(7,496 |
) |
|
|
(67,788 |
) |
|
Public cord blood banking
|
|
|
(243,086 |
) |
|
|
(243,087 |
) |
|
|
|
|
|
|
|
|
|
|
Total operating income
|
|
$ |
920,122 |
|
|
$ |
3,056,995 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
410,366 |
|
|
$ |
995,437 |
|
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$ |
410,366 |
|
|
$ |
995,437 |
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
(303,072 |
) |
|
$ |
(3,821,660 |
) |
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total income tax expense
|
|
$ |
(303,072 |
) |
|
$ |
(3,821,660 |
) |
|
|
|
|
|
|
|
|
|
The following table shows the assets by segment as of
August 31, 2018 and November 30, 2017:
|
|
|
|
|
|
|
|
|
| |
|
As of August 31,
2018 |
|
|
As of November 30,
2017 |
|
|
Assets
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
26,300,294 |
|
|
$ |
23,360,715 |
|
|
Prepacyte®-CB
|
|
|
469,998 |
|
|
|
549,282 |
|
|
Public cord blood banking
|
|
|
15,880,068 |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$ |
42,650,360 |
|
|
$ |
23,909,997 |
|
|
|
|
|
|
|
|
|
|
The following table shows, by segment: net revenue, cost of sales,
depreciation and amortization, operating profit, interest expense,
and income tax (expense) benefit for the three months and nine
months ended August 31, 2017:
|
|
|
|
|
|
|
|
|
| |
|
For the three months
For the three months
ended August 31, 2017 |
|
|
For the nine months
ended August 31, 2017 |
|
|
Net revenue
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
6,780,565 |
|
|
$ |
18,567,285 |
|
|
Prepacyte®-CB
|
|
|
115,376 |
|
|
|
342,031 |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total net revenue
|
|
$ |
6,895,941 |
|
|
$ |
18,909,316 |
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,771,403 |
|
|
$ |
4,681,276 |
|
|
Prepacyte®-CB
|
|
|
206,072 |
|
|
|
404,262 |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total cost of sales
|
|
$ |
1,977,475 |
|
|
$ |
5,085,538 |
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
24,295 |
|
|
$ |
69,734 |
|
|
Prepacyte®-CB
|
|
|
9,064 |
|
|
|
27,191 |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total depreciation and amortization
|
|
$ |
33,359 |
|
|
$ |
96,925 |
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
1,552,168 |
|
|
$ |
3,850,206 |
|
|
Prepacyte®-CB
|
|
|
(99,935 |
) |
|
|
(89,597 |
) |
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total operating income
|
|
$ |
1,452,233 |
|
|
$ |
3,760,609 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
314,890 |
|
|
$ |
937,248 |
|
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total interest expense
|
|
$ |
314,890 |
|
|
$ |
937,248 |
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
|
|
|
|
|
|
|
|
|
|
Umbilical cord blood and cord tissue stem cell service
|
|
$ |
(490,558 |
) |
|
$ |
(1,128,012 |
) |
|
Prepacyte®-CB
|
|
|
— |
|
|
|
— |
|
|
Public cord blood banking
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Total income tax expense
|
|
$ |
(490,558 |
) |
|
$ |
(1,128,012 |
) |
|
|
|
|
|
|
|
|
|
|